. Dose-response and toxicity trials to select optimal adjuvant dose for in vitro bmDC studies. (A) BmDCs derived from 3 different animals were incubated with different concentrations of adjuvants and cytokine levels in cell culture supernatants were measured by ELISA (data expressed as ng/ml). The adjuvant Poly I:C alone failed to induce significant levels of cytokine production by bmDCs and it was thus not included in Panel A. Representative cytokines were chosen (upon the type 1/type 2 profiles) for other adjuvants. (B) Cytotoxicity was evaluated by the lactate dehydrogenase (LDH) enzyme test after bmDC activation with adjuvant concentrations which gave the highest production of cytokine in (A), that is: Quil A® : 5 μg/mL; Alhydrogel®: 50 μg/ mL; TiterMax Gold® : 100 μL/well of emulsion; and Stimune® : 100 μL/well of emulsion. Poly I:C was used at 50 μg/ mL. Data of individuals are presented including mean ± SEM (n = 3). 
